Parathyroid hormone synthesis pathway (PTH synthesis pathway)

The Parathyroid hormone (PTH) synthesis pathway is a complex endocrine process primarily occurring within the chief cells of the parathyroid glands to regulate systemic calcium and phosphate levels (StatPearls, 2023). This pathway is tightly controlled by extracellular calcium concentrations, which are detected by the G protein-coupled Calcium-sensing receptor (CaSR) on the cell surface (Silver & Naveh-Many, 2013). When calcium levels are high, CaSR activation triggers intracellular signaling that inhibits both the secretion of pre-formed PTH and the transcription of the PTH gene. Additionally, the active form of Vitamin D, 1,25-dihydroxyvitamin D3, binds to the nuclear Vitamin D receptor (VDR) to directly suppress PTH gene expression (NIH, 2022). Dysregulation of this pathway leads to conditions such as primary hyperparathyroidism or secondary hyperparathyroidism, which is a common complication of chronic kidney disease. Therapeutic strategies targeting this pathway include calcimimetics like cinacalcet, which increase the sensitivity of CaSR to calcium, and Vitamin D analogs that activate VDR. These interventions aim to lower pathologically elevated PTH levels to prevent bone resorption and vascular calcification. Monitoring the pathway involves measuring serum intact PTH, calcium, and phosphorus levels to ensure therapeutic efficacy and safety (KDIGO, 2017).

Other names

PTH synthesis and secretion pathwayParathyroid hormone regulatory axisCalcium-PTH-Vitamin D axis

Drugs targeting this pathway primarily act as agonists of the Calcium-sensing receptor (CaSR) to increase its sensitivity to extracellular calcium, thereby inhibiting PTH release and synthesis (e.g., calcimimetics), or as agonists of the Vitamin D receptor (VDR) to transcriptionally repress the PTH gene (e.g., Vitamin D analogs) (Silver & Naveh-Many, 2013; StatPearls, 2023).